Price (delayed)
$25.46
Market cap
$713.07M
P/E Ratio
115.73
Dividend/share
N/A
EPS
$0.22
Enterprise value
$644.85M
Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently
There are no recent dividends present for CSTL.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.